MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Axsome Therapeutics, Inc. (NASDAQ: AXSM)*
Organization & Developments: Axsome
Parents
Axsome Therapeutics, Inc. (NASDAQ: AXSM)*
Children
*Focused on developing therapies for the management of central nervous system {CNS} disorders
2017: Axsome Therapeutics Sweetens The Deal For Investors - Axsome Therapeutics (NASDAQ:AXSM)
2018: Axsome AXSM shares slump on discontinuation of late-stage trial;_biopharmcatalyst
2018: Axsome Therapeutics (AXSM)_seekingalpha.com
2018: Axsome Therapeutics Goes 1 For 2. Now What? - Bret Jensen
2018: Still Hope For This ~$2.50 Biotech Concern?_seekingalpha.com
2018: What's Ahead For Axsome Therapeutics_seekingalpha.com
2019: Axsome sees in treatment-resistant depression study results in Q1_seekingalpha.com
2019: Axsome Therapeutics: AXS-05's Potential In Nicotine Addiction_seekingalpha.com
2019: Axsome Therapeutics: AXS-05’s Nicotine Addiction Trial, Two Important Catalysts Coming Up_seekingalpha.com
2019: Axsome Therapeutics: Is There Upside Left After A Monster Run? - ONeil Trader
2019: Axsome Therapeutics: Still 5 Catalysts Ahead In 2019_seekingalpha.com
2019: Axsome: A Flurry Of Powerful Catalysts_seekingalpha.com
2019: Axsome: Reasons For Caution Following MDD Data_seekingalpha.com
2019: Biotech Analysis Central Preview Series: Axsome Therapeutics_seekingalpha.com
2019: Revisiting Axsome Therapeutics_seekingalpha.com
2020: Axsome in-licenses U.S. rights to Pfizer's reboxetine_seekingalpha.com
2020: Axsome shares rocket up on a surprise win for late-stage Alzheimer’s agitation study
2020: Axsome Therapeutics: An Excellent Pipeline Of Approvable CNS Products
2020: Axsome Therapeutics: There Still Remains A Lot Of Upside Potential For 2020
2020: Axsome Therapeutics: There Still Remains A Lot Of Upside Potential For 2020_seekingalpha.com
2020: The Play On Axsome Therapeutics
2021: Axsome: Robust Fundamental Improvements
2021: Circling Back On Axsome Therapeutics
2022: Axsome Therapeutics Stock Rockets As Its First FDA Approval Looks Imminent
2022: Axsome Therapeutics: All Eyes On Auvelity Launch_ seekingalpha.com
2022: Axsome Therapeutics: Clear Path Ahead For AXS07_seekingalpha.com
2022: Axsome: In The Middle Of Uncertainty Is Your Biggest Opportunity_seekingalpha.com
2022: Axsome: More Catalysts Stacking For 2023_seekingalpha.com
2022: Axsome: Ramifications Of Recent Biotech Deals_seekingalpha.com
2022: Axsome: Strong Earnings Signal More Upside_seekingalpha.com
2022: With FDA approval, Axsome touts Auvelity as a potential game-changing depression treatment
2023: Axsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade)_seekingalpha.com
2023: Axsome Therapeutics: Things Are Coming Together Nicely_ seekingalpha.com
2023: Axsome Update: Buy At Dips And Hold Forever
2023: Axsome: A Lot More Upside In 2023_seekingalpha.com
2023: Axsome: Show Me Another Company With Such A Stack Of Catalysts_ seekingalpha.com
2024: A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics
2024: Axsome Therapeutics Announces FDA Acceptance of NDA
2024: Axsome Therapeutics Getting Closer To Key Technical Measure
2024: Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell_seekingalpha.com
2024: Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results
2024: Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit
2024: Axsome Therapeutics' CNS Portfolio Poised for Major Growth
2024: Axsome Therapeutics' SWOT analysis: strong growth, pipeline potential lift stock
2024: Axsome: AXS-07 And Its Upcoming Second PDUFA
2024: Axsome: AXS-07 And Its Upcoming Second PDUFA
2024: Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data_ seekingalpha.com
2024: Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
2024: Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)
2024: Axsome's sleep disorder drug succeeds in late-stage trial, shares rise
2025: Axsome plots new fibromyalgia trial after FDA refuses to review former Pfizer candidate
2025: Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
2025: Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Jumps
*Key People: Axsome
Finance & Acquisitions: Axsome